Elisabeth B. Stougaard - Publications

GLP-1 receptor agonists in patients with Type 2 diabetes: cardiorenal protection versus ocular safety.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 18, 2026

The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.

Journal: Diabetes, obesity & metabolism

Published: May 09, 2025

Combining SGLT2is, GLP1-RAs and nsMRAs in Diabetes: A Scoping Review of Current and Future Perspectives.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: January 06, 2025

Modeling Cardiovascular Protection With SGLT Inhibition in Type 1 Diabetes: A Risk-Based Approach to Guide Therapy?

Journal: Diabetes care

Published: December 20, 2024

Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: August 29, 2024

Effects of probiotics and fibers on markers of nephropathy, inflammation, intestinal barrier dysfunction and endothelial dysfunction in individuals with type 1 diabetes and albuminuria. The ProFOS Study.

Journal: Journal of diabetes and its complications

Published: August 15, 2024

Slowing the progression of diabetic and non-diabetic kidney disease: A summary of the current evidence base for sodium-glucose co-transporter-2 inhibitors.

Journal: Diabetes, obesity & metabolism

Published: August 14, 2024

Time Trends in the Incidence of Diabetic Ketoacidosis Leading to Hospital Admission Among Adults With Type 1 Diabetes: A Nationwide Danish Register Study.

Journal: Diabetes care

Published: March 17, 2023

Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.

Journal: Diabetes, obesity & metabolism

Published: January 24, 2023

Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.

Journal: Diabetes & vascular disease research

Published: October 20, 2022

Lower Blood Oxygen Saturation is Associated With Microvascular Complications in Individuals With Type 1 Diabetes.

Journal: The Journal of clinical endocrinology and metabolism

Published: July 14, 2022

Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines.

Journal: Journal of diabetes and its complications

Published: May 17, 2022